Bioventus Inc. Class A Common Stock (BVS) is a publicly traded Healthcare sector company. As of May 21, 2026, BVS trades at $10.92 with a market cap of $720.16M and a P/E ratio of 25.49. BVS moved +2.44% today. Year to date, BVS is +44.52%; over the trailing twelve months it is +56.51%. Its 52-week range spans $5.81 to $14.38. Analyst consensus is strong buy with an average price target of $14.33. Rallies surfaces BVS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Hedge funds tracked by Rallies that own BVS include Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Bioventus Inc. Class A Common Stock.
| Metric | Value |
|---|---|
| Price | $10.92 |
| Market Cap | $720.16M |
| P/E Ratio | 25.49 |
| EPS | $0.43 |
| Dividend Yield | 0.61% |
| 52-Week High | $14.38 |
| 52-Week Low | $5.81 |
| Volume | 10 |
| Avg Volume | 0 |
| Revenue (TTM) | $576.30M |
| Net Income | $34.54M |
| Gross Margin | 68.69% |
4 analysts cover BVS: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $14.33.